PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharmaceuticals, Inc. (PMVP) Healthcare & Pipeline Overview

PMV Pharmaceuticals, Inc. is a biotechnology company specializing in precision oncology, focusing on developing small molecule therapies targeting p53 mutations. Their lead candidate, PC14586, aims to correct the Y220C mutation, offering a novel approach in cancer treatment and positioning them in a competitive biotech landscape.

What Is the Investment Thesis for PMVP?

PMV Pharmaceuticals, Inc. presents a focused investment opportunity within the precision oncology space, targeting p53 mutations with its lead candidate, PC14586. The company's approach to correcting the Y220C mutation and restoring wild-type p53 function offers a novel therapeutic strategy. Key value drivers include the successful clinical development and regulatory approval of PC14586, as well as the advancement of its other mutant p53 programs. Upcoming catalysts include the progression of PC14586 through clinical trials and the potential for positive data readouts. However, potential risks include clinical trial failures, regulatory hurdles, and competition from other companies developing cancer therapies. The company's market capitalization of $64.26M reflects its early-stage development profile and associated risks.

Based on FMP financials and quantitative analysis

PMVP Key Highlights

• PMV Pharmaceuticals is focused on precision oncology, specifically targeting p53 mutations, which are prevalent in various cancer types.
• The lead product candidate, PC14586, aims to correct the Y220C mutation in the p53 protein, restoring its tumor-suppressing function.
• The company is developing multiple mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, indicating a broad approach to targeting p53 mutations.
• PMV Pharmaceuticals operates with a relatively small team of 47 employees, suggesting a lean and focused operational structure.
• The company's market capitalization is $0.08 billion, reflecting its early-stage development and associated investment risks.

Who Are PMVP's Competitors?

PMVP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PMVP's Key Strengths?

• Focus on a specific and well-defined target (p53 mutations).
• Novel approach to correcting mutant p53 proteins and restoring wild-type function.
• Lead product candidate, PC14586, in clinical development.
• Experienced management team with expertise in oncology drug development.

What Are PMVP's Weaknesses?

• Early-stage development company with limited revenue.
• Reliance on the success of its lead product candidate.
• Small team size and limited resources.
• High risk of clinical trial failures and regulatory hurdles.

What Could Drive PMVP Stock Higher?

• Clinical trial data releases for PC14586.
• Initiation of clinical trials for additional mutant p53 programs.
• Potential strategic partnerships or collaborations.
• Continued research and development efforts to expand the company's pipeline.

What Are the Key Risks for PMVP?

• Financial-distress signal — its Altman Z-Score of -3.79 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-69.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or delays.
• Regulatory setbacks or rejection of marketing applications.
• Competition from other companies developing cancer therapies.
• Patent challenges or intellectual property disputes.
• Dependence on the success of its lead product candidate.
• Limited financial resources and reliance on external funding.

What Are the Growth Opportunities for PMVP?

• Growth Opportunity 1: Successful Clinical Development of PC14586: The successful completion of clinical trials for PC14586 and subsequent regulatory approval represents a significant growth opportunity for PMV Pharmaceuticals. The market for therapies targeting p53 mutations is substantial, given the prevalence of these mutations in various cancers. Positive clinical data demonstrating the efficacy and safety of PC14586 could lead to significant market adoption and revenue generation. The timeline for this growth opportunity is dependent on the pace of clinical trials and regulatory review processes.
• Growth Opportunity 2: Expansion of Mutant p53 Programs: PMV Pharmaceuticals' development of multiple mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, offers a growth opportunity by expanding its pipeline and addressing a broader range of p53 mutations. Each program represents a potential new therapy with its own market opportunity. The timeline for this growth opportunity depends on the progress of preclinical and clinical development for each program.
• Growth Opportunity 3: Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with other biotechnology or pharmaceutical companies could provide PMV Pharmaceuticals with access to additional resources, expertise, and funding. These partnerships could accelerate the development and commercialization of its therapies. The timing and impact of this growth opportunity are dependent on the specific partnerships that are formed.
• Growth Opportunity 4: Geographic Expansion: Expanding its geographic reach beyond the United States could provide PMV Pharmaceuticals with access to new markets and patient populations. This could involve conducting clinical trials in other countries or establishing commercial operations in new regions. The timeline for this growth opportunity depends on the company's strategic priorities and regulatory considerations in different countries.
• Growth Opportunity 5: Acquisition or Licensing of Complementary Technologies: Acquiring or licensing complementary technologies could enhance PMV Pharmaceuticals' capabilities and expand its product pipeline. This could involve technologies related to drug discovery, diagnostics, or delivery systems. The timing and impact of this growth opportunity are dependent on the availability of suitable technologies and the company's strategic priorities.

What Opportunities Does PMVP Have?

• Growing market for precision oncology and targeted cancer therapies.
• Potential for strategic partnerships and collaborations.
• Expansion of its pipeline through the development of additional mutant p53 programs.
• Geographic expansion into new markets.

What Threats Does PMVP Face?

• Competition from other biotechnology and pharmaceutical companies.
• Clinical trial failures and regulatory setbacks.
• Patent challenges and intellectual property disputes.
• Changes in the regulatory landscape and reimbursement policies.

What Are PMVP's Competitive Advantages?

• Proprietary small molecule therapies targeting p53 mutations.
• Intellectual property protection through patents and other forms of exclusivity.
• Expertise in precision oncology and the development of targeted cancer therapies.
• First-mover advantage in developing therapies that correct mutant p53 proteins.

What Does PMVP Do?

PMV Pharmaceuticals, Inc., established in 2013 (originally as PJ Pharmaceuticals, Inc. before rebranding in July 2013), is a precision oncology company dedicated to discovering and developing innovative small molecule therapies that target and correct p53 mutations in cancer. The company's foundational mission revolves around addressing the unmet medical needs of patients with cancers driven by p53 mutations, a common occurrence across various cancer types. PMV Pharmaceuticals' lead product candidate, PC14586, is a small molecule designed to correct the p53 protein containing the Y220C mutation, thereby restoring wild-type p53 function. This approach aims to reinstate the tumor-suppressing capabilities of the p53 protein, which are often compromised by mutations. In addition to PC14586, PMV Pharmaceuticals is actively developing other mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as exploring other p53 hotspot mutations. These programs reflect the company's commitment to a broad and comprehensive approach to targeting p53 mutations in cancer. Headquartered in Cranbury, New Jersey, PMV Pharmaceuticals operates with a team of 47 employees, focusing on preclinical and clinical development activities. The company's research and development efforts are geared towards creating tumor-agnostic therapies that can be applied across different cancer types sharing the same p53 mutation.

What Products and Services Does PMVP Offer?

• Discovers and develops small molecule therapies for p53 mutations in cancer.
• Focuses on precision oncology, targeting the genetic and molecular characteristics of individual tumors.
• Develops tumor-agnostic therapies that can be applied across different cancer types sharing the same p53 mutation.
• Creates therapies that correct mutant p53 proteins and restore wild-type p53 function.
• Conducts preclinical and clinical development activities to advance its therapies.
• Aims to address the unmet medical needs of patients with cancers driven by p53 mutations.

How Does PMVP Make Money?

• Develops and patents novel small molecule therapies targeting p53 mutations.
• Conducts preclinical and clinical research to demonstrate the safety and efficacy of its therapies.
• Seeks regulatory approval from agencies such as the FDA to market its therapies.
• May partner with other pharmaceutical companies for commercialization and distribution.

What Industry Does PMVP Operate In?

PMV Pharmaceuticals operates within the biotechnology industry, specifically in the precision oncology segment. This segment focuses on developing targeted therapies based on the genetic and molecular characteristics of individual tumors. The market for precision oncology is growing, driven by advancements in genomic sequencing and personalized medicine. PMV Pharmaceuticals' focus on p53 mutations positions it within a niche area of precision oncology. The competitive landscape includes other biotechnology companies developing targeted cancer therapies, as well as pharmaceutical companies with broader oncology portfolios.

Who Are PMVP's Key Customers?

• Patients with cancers driven by p53 mutations.
• Oncologists and other healthcare professionals who treat cancer patients.
• Hospitals and cancer centers that provide cancer care.
• Pharmaceutical companies that may partner with PMV Pharmaceuticals for commercialization.

FY2026 estForward Outlook

Wall Street analysts project PMV Pharmaceuticals, Inc. revenue of about $2.9M for fiscal 2026, with EPS near $-1.46. The estimate reflects 3 contributing analysts.

PMVP Valuation & Market Position

With a $64.26M market cap, PMV Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, PMVP's quantitative score of 27/100 is below the peer average of 76/100.

ROE -69%Key Financial Metrics

Return on equity for PMV Pharmaceuticals, Inc. stands at -69.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -81.1%, showing how much profit it generates from its asset base. A current ratio of 11.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -120.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

PMV Pharmaceuticals, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -3.79 places it in the distress zone, a signal of elevated financial risk.

Company Profile

PMV Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Princeton, US. The company is led by CEO David H. Mack. PMVP has traded publicly since 2020.

PMVP Financials

PMVP Latest News

PMVP Analyst Consensus

PMVP MoonshotScore

What Investors Ask About PMV Pharmaceuticals, Inc. (PMVP) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources